Hubei Biocause Pharmaceutical Bundle
Who Really Owns Hubei Biocause Pharmaceutical?
Unraveling the ownership structure of a Hubei Biocause Pharmaceutical SWOT Analysis is key to understanding its strategic moves and market influence. The company's 2015 acquisition of a significant stake in Guohua Life Insurance marked a pivotal shift, reshaping its business focus and highlighting the deep connection between ownership and strategic direction. This analysis dives deep into the evolution of this Pharmaceutical company's ownership.
This report will explore the intricate details of Biocause Pharmaceutical ownership, examining the roles of founders, key investors, and public shareholders. We'll investigate the significant changes over time to provide a comprehensive understanding of who truly controls this entity within the Chinese pharmaceutical industry. Understanding the company's ownership is crucial for investors and stakeholders alike, offering insights into its future trajectory and financial health. Learn more about the history of Hubei Biocause Pharmaceutical ownership and find the owner of Biocause Pharmaceutical.
Who Founded Hubei Biocause Pharmaceutical?
The story of Hubei Biocause Pharmaceutical begins on November 18, 1993, marking its inception as a Pharmaceutical company. While the exact details of the founders and their initial equity distribution remain somewhat obscure, the company's trajectory and ownership structure have evolved significantly over time.
The company's listing on the Shenzhen Stock Exchange on November 12, 1996, was a pivotal moment, opening new avenues for capital and influencing its future direction. The early ownership dynamics, including the roles of angel investors or initial backers, are not explicitly detailed in available records, but the subsequent strategic moves provide insights into the individuals and entities shaping Biocause Pharmaceutical ownership.
The shift into the insurance sector, particularly through the acquisition of a controlling stake in Guohua Life Insurance, highlights the influence of key shareholders. This strategic diversification, supported by a private placement, significantly increased the holdings of the Liu family, indicating their enduring involvement. Yiqian Liu, as Chairman of the Board and a major shareholder, underscores the family's central role in the company's leadership and ownership framework.
Founding Date
Hubei Biocause Pharmaceutical was founded on November 18, 1993.
Listing on Stock Exchange
The company was listed on the Shenzhen Stock Exchange on November 12, 1996.
Key Shareholder
Yiqian Liu is identified as Chairman and a significant shareholder.
Strategic Shift
The company expanded into the insurance sector through the acquisition of Guohua Life Insurance.
Ownership Influence
Private placements increased the holdings of the Liu family.
Initial Focus
The initial focus was on pharmaceutical research, development, and manufacturing.
Ownership and Strategic Direction
Understanding the ownership structure of Hubei Biocause Pharmaceutical is key to grasping its strategic direction. The Liu family's significant stake and leadership roles suggest a strong influence over the company's decisions, including its diversification into the insurance industry. For further insights, consider exploring the Marketing Strategy of Hubei Biocause Pharmaceutical.
- The company's shift into insurance indicates a strategic diversification beyond its initial pharmaceutical focus.
- The Liu family's increased holdings highlight their growing influence on the company's strategic priorities.
- Yiqian Liu's role as Chairman and a major shareholder underscores the family's control.
- The evolution of Biocause Pharmaceutical ownership reflects the changing dynamics within the Chinese pharmaceutical industry.
Hubei Biocause Pharmaceutical SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Hubei Biocause Pharmaceutical’s Ownership Changed Over Time?
The ownership structure of Hubei Biocause Pharmaceutical has evolved significantly since its initial public offering on November 12, 1996. Currently, private companies hold the largest share, controlling approximately 45% of the company's stock. Sunline Group Co., Ltd. stands out as the largest single shareholder, also with a 45% stake, indicating a strong influence over the company's strategic direction. This concentration of ownership within private entities, particularly with Sunline Group, is a key aspect of understanding the company's governance and operational decisions.
The evolution of Biocause Pharmaceutical ownership includes a notable event in 2015. The company acquired a 44% stake in Guohua Life Insurance for $1.2 billion. This strategic move, funded through a private placement, significantly increased the Liu family's holdings in Hubei Biocause from 24% to 76%. This acquisition marked a significant diversification, expanding the company's business scope beyond its original pharmaceutical and chemical focus to include life, health, and accident insurance. This shift underscores the dynamic nature of the company's ownership and strategic direction.
| Shareholder | Percentage of Shares Outstanding | Role/Relationship |
|---|---|---|
| Sunline Group Co., Ltd. | 45% | Largest Single Shareholder |
| Second Largest Shareholder | 11% | - |
| Yiqian Liu | 10% | Chairman of the Board, Third-Largest Shareholder |
| Insiders | 23% | Collective Ownership |
| Institutional Investors | Less than 5% | - |
| General Public | 27% | Primarily Individual Investors |
The ownership structure of Hubei Biocause Pharmaceutical reveals a landscape where private entities and key individuals hold considerable influence. The substantial ownership by Sunline Group and the significant stake held by Chairman Yiqian Liu, along with the collective holdings of insiders, highlight the control within the company. While institutional investors have a presence, the majority of the shares are held by private entities and the general public. For a deeper dive into the competitive environment, consider exploring the Competitors Landscape of Hubei Biocause Pharmaceutical.
Key Takeaways on Biocause Pharmaceutical Ownership
Private companies, particularly Sunline Group, have a significant influence on the company's direction.
- Yiqian Liu, the Chairman, is a major shareholder, indicating key individual influence.
- The 2015 acquisition of a stake in Guohua Life Insurance expanded the company's business scope.
- As of December 31, 2024, the trailing 12-month revenue was $5.86 billion, with a net income of -$107.53 million.
- Understanding the ownership structure is crucial for investors and stakeholders in the Chinese pharmaceutical industry.
Hubei Biocause Pharmaceutical PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Hubei Biocause Pharmaceutical’s Board?
The current board of directors of Hubei Biocause Pharmaceutical plays a critical role in the company's governance structure. Yiqian Liu, the Chairman of the Board, is also a significant shareholder. Fei Long, holding multiple key positions including Chief Financial Officer, General Manager, and Secretary of the Board, is also a Director. The board also includes independent directors such as Bing Hu, Haihua Jiang, and Xiaomiao Zhang.
The composition of the board and its alignment with major shareholders highlights the importance of understanding Biocause Pharmaceutical ownership. This structure influences decision-making and strategic direction within the company. The presence of independent directors provides a degree of oversight, but the influence of major shareholders remains significant.
| Director | Title | Shareholder Status |
|---|---|---|
| Yiqian Liu | Chairman of the Board | Significant Shareholder (10% as of March 6, 2025) |
| Fei Long | Chief Financial Officer, General Manager, Secretary of the Board, Director | Director |
| Bing Hu | Independent Director | Independent |
| Haihua Jiang | Independent Director | Independent |
| Xiaomiao Zhang | Independent Director | Independent |
The voting power at Hubei Biocause Pharmaceutical is heavily influenced by its major shareholders. Sunline Group Co., Ltd. is the largest single shareholder, with a 45% stake. Private companies collectively own 45% of the company, and the top two shareholders combined hold a majority stake of 56%. Insiders, including board members, own 23% of the company. This concentration of ownership suggests that these entities have substantial control over the company's strategic direction. Further details about the company's ownership can be found in this article about Hubei Biocause Pharmaceutical.
Ownership Influence at Hubei Biocause Pharmaceutical
The ownership structure of Hubei Biocause Pharmaceutical significantly impacts its governance and strategic decisions.
- Sunline Group Co., Ltd. holds a significant 45% stake.
- Private companies collectively own 45% of the company.
- The top two shareholders control a majority stake of 56%.
- Insiders, including board members, own 23% of the company.
Hubei Biocause Pharmaceutical Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Hubei Biocause Pharmaceutical’s Ownership Landscape?
Over the last few years, several significant developments have reshaped the ownership structure and strategic direction of Hubei Biocause Pharmaceutical. In 2024, the company initiated an equity buyback plan, allocating CNY 100 million. This plan concluded on April 30, 2025, with the repurchase of 36.49 million shares, representing 0.74% of its total shares. This move suggests an effort to consolidate ownership or boost shareholder value.
A major shift in the company's focus is its growing involvement in the insurance sector. While initially a pharmaceutical company, Hubei Biocause Pharmaceutical now primarily operates in the life, health, and accident insurance businesses through its subsidiaries, Guohua Life Insurance and Huarui Insurance. In early 2025, CHINA BEST Life Insurance, a subsidiary, reported approximately 8.035 billion RMB in cumulative original insurance premium income from January 1 to February 28, 2025. For the full year of 2024, this figure reached approximately 34.639 billion yuan. This strategic pivot significantly alters the company's risk profile, aligning its ownership interests more closely with the financial services industry. If you want to learn more about the company's strategic moves, you can check out the Target Market of Hubei Biocause Pharmaceutical.
| Metric | Value | Date |
|---|---|---|
| Stock Price | $0.38 | April 30, 2025 |
| Market Capitalization | $1.86 billion | April 30, 2025 |
| Trailing Twelve-Month Revenue | $5.86 billion | September 30, 2024 |
| Net Income | -$107.53 million | September 30, 2024 |
Recent events also highlight challenges related to financial reporting. In May 2025, trading of the company's stock was suspended due to the inability to release its 2024 annual report and the 2025 first-quarter report within the required timeframe. This situation triggered an investigation by the China Securities Regulatory Commission. The outcome of this investigation could lead to further changes in ownership or corporate governance. The stock price on April 30, 2025, was $0.38, with a market capitalization of $1.86 billion. As of September 30, 2024, the trailing twelve-month revenue was $5.86 billion, and the net income was -$107.53 million.
Key Development
Equity buyback plan for CNY 100 million, repurchasing 0.74% of shares by April 30, 2025.
Strategic Shift
Transition from pharmaceutical to insurance, focusing on life, health, and accident insurance.
Financial Reporting Issues
Suspension of stock trading in May 2025 due to delayed financial reports.
Market Performance
Stock price of $0.38 and market capitalization of $1.86 billion as of April 30, 2025.
Hubei Biocause Pharmaceutical Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Hubei Biocause Pharmaceutical Company?
- What is Competitive Landscape of Hubei Biocause Pharmaceutical Company?
- What is Growth Strategy and Future Prospects of Hubei Biocause Pharmaceutical Company?
- How Does Hubei Biocause Pharmaceutical Company Work?
- What is Sales and Marketing Strategy of Hubei Biocause Pharmaceutical Company?
- What is Brief History of Hubei Biocause Pharmaceutical Company?
- What is Customer Demographics and Target Market of Hubei Biocause Pharmaceutical Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.